Image of a molecule

Galecto Biotech Strengthens Executive Team with Appointment of Richard Marshall as Chief Medical Officer

(COPENHAGEN – May 21, 2018) – Galecto Biotech AB, the leading developer of galectin modulators for the treatment of severe diseases, including fibrosis and cancer, today announced the appointment of Richard Marshall, MD, PhD, as Chief Medical Officer. Dr Marshall joins Galecto with more than 15 years of experience across drug discovery, clinical development and business development in various positions at Glaxo Smithkline (GSK).

News